Value_investing

Stock and Earning Analysis

    • Value_investingValue_investing
      ·04-11 19:43

      The dividend stocks T & PFE are seriously undervalued!

      图片With the Fed expected to cut rates, high-yield dividend stocks are poised for a major rally. Fund managers are eager to snap up these juicy dividends in a low-rate environment. $AT&T Inc(T)$ , the telecom giant, and $Pfizer(PFE)$ , the drugmaker, seem like steals right now. Both of these stocks offer yields above 6%. Once rates start to drop, fund managers will be all over them like flies on honey!1.AT&T AT&T, a household name in the US telecom industry, is trading at a significant discount. While the industry average trailing PE ratio is 11.7, AT&T's PE ratio stands at just 8.84.This low valuation, coupled with AT&T's impressive 6.4% annualized yield, makes it a potential gem for both
      5611
      Report
      The dividend stocks T & PFE are seriously undervalued!
    • Value_investingValue_investing
      ·04-10

      Earnings season will be a catalyst for US stocks

      图片The earnings season is coming, and it could be just the catalyst needed to take the US stock market to the next level!This week, companies like $Delta Air Lines(DAL)$ , $Canopy Growth Corporation(CGC)$ , $JPMorgan Chase(JPM)$ , and $Fastenal(FAST)$ are all set to release their first-quarter earnings, and chances are they'll beat analysts' expectations.Chris Senyek, the chief investment strategist at Wolfe Research, said:Over the past four quarters, the S&P 500 has beaten earnings estimates by an average of 7.1%. And since analysts have already trimmed their first-quarter forecasts by 2.5%, it's likely we'll see some p
      6182
      Report
      Earnings season will be a catalyst for US stocks
    • Value_investingValue_investing
      ·04-10

      Apple is the cheapest stock among the "Magnificent Seven"

      图片Guess which stock is the cheapest among the tech "Magnificent Seven"? The answer is $Apple(AAPL)$ !Here's why Apple's stock is relatively cheaper compared to its top tech peers.Apple's Discounted ValuationFor younger, unprofitable companies, the price-to-sales ratio might be a good indicator to assess stocks and their correlation with revenue. But for more mature, industry-leading companies, the price-to-earnings ratio is probably a better metric. So, combining P/E with P/FCF ratio gives a more accurate picture of the company's valuation.Not long ago, $Alphabet(GOOG)$ $Alphabet(GOOGL)$ was the cheapest stock among the "Magnificent Seven". But its share price h
      1.29KComment
      Report
      Apple is the cheapest stock among the "Magnificent Seven"
    • Value_investingValue_investing
      ·04-09

      What will happen to the market after the Big sell-off?

      Finally, the US stock market has taken a tumble. This drop was led by the previously rallying AI stocks. In fact, $NVIDIA Corp(NVDA)$ was stalling a bit when it hit the $1000 mark, and $Advanced Micro Devices(AMD)$ took a big tumble, falling over 8%.Meanwhile, gold has hit a record high. Logically speaking, with the Fed's expectation of a rate cut slipping, gold's rise seems a bit odd. Maybe it's a sign of market fear, with investors seeking safe havens.1.Look for the bad news after the crashOn the news side, the March ISM non-manufacturing PMI in the US was lower than expected, while the previously released manufacturing PMI exceeded expectations and entered the expansion zone for the first time. Theoreti
      3.09KComment
      Report
      What will happen to the market after the Big sell-off?
    • Value_investingValue_investing
      ·04-06

      How to Invest in Biotech Stocks and ETFs?

      图片Biotech is one of the most innovative industries out there. From 2012 to 2022, thanks to the innovation boom like the Human Genome Project and ultra-low interest rates, biotech stocks have significantly outperformed $S&P 500(.SPX)$ . And now, with interest rate cuts looming, biotech stocks and ETFs are poised for an unmissable investment opportunity.According to Grand View Research, the global biotech market will grow to $3.88 trillion at a compound annual growth rate (CAGR) of 13.96% during the period 2024-2030. In addition, Verified Market Research expects the size of the global biotech market to exceed $5.25 trillion by 2030. As for the nano-medicine segment, Precendence Research forecasts it'll grow to $183.11 billion with an 8.13% CAGR
      371Comment
      Report
      How to Invest in Biotech Stocks and ETFs?
    • Value_investingValue_investing
      ·04-04

      Long-term investors should buy UNH on dips!

      图片Recently, $UnitedHealth(UNH)$ 's stock price has been shaking and dropping from its 52-week high. However, looking at the bigger picture, the "danger" UnitedHealth is facing right now could very well be an "opportunity" for investors.A key player in the US healthcare systemAs the largest health insurance company in the US, it provides medical services to 152 million people and has expanded its business from insurance to include healthcare services and technology systems.UnitedHealth is deeply integrated into the US healthcare system, which serves as its strong moat. Long-term investors do not need to react to the recent cyber attack incident.Don’t let down investorsFinancially speaking, UnitedHealth is a stellar company with annual revenue exceed
      25.42K6
      Report
      Long-term investors should buy UNH on dips!
    • Value_investingValue_investing
      ·04-03

      Healthcare stocks "Magnificent Seven" - LLY, NVO, VRTX, ABBV, ISRG, HCA & UNH

      图片You might know“Magnificent Seven”, the tech titans in the US stock market, and these seven healthcare stocks definitely share the following characteristics. They’re the leaders in their niches, have raked in obscene returns over the past decade, and their futures look as bright as a billion-dollar smile!1+2.Eli Lilly and Novo NordiskWhen it comes to $Eli Lilly(LLY)$ and $Novo-Nordisk A/S(NVO)$ , these two giants in the diabetes and obesity treatment market are all about “weight loss drugs.” And they’re both on track to becoming trillion-dollar stocks in the next decade. Lilly’s Zepbound got approved last year, while Novo Nordisk’s Wegovy sales are skyrocketing, and they’ve even reported promising phase on
      324Comment
      Report
      Healthcare stocks "Magnificent Seven" - LLY, NVO, VRTX, ABBV, ISRG, HCA & UNH
    • Value_investingValue_investing
      ·04-02

      Us stock bubble alert! Beware of these 10 most highly valued stocks!

      图片The AI craze is heating up and pushing US stocks to new highs, but some investors are starting to worry that a bubble might be forming. The skyrocketing valuations are making them nervous, especially considering the more than 25% surge in $S&P 500(.SPX)$ since late October.Economist David Rosenberg pointed out three glaring divergences in the stock market earlier this month, hinting at an inevitable pullback. Despite the strong performance of $DJIA(.DJI)$ and $S&P 500(.SPX)$ , the Dow Jones Transportation Average, a bellwether of economic health, is lagging. The HYG/TLT ratio is trending down, and even the tech sector is starting to show weakness.His US
      3.37K1
      Report
      Us stock bubble alert! Beware of these 10 most highly valued stocks!
    • Value_investingValue_investing
      ·03-29

      CRSP, PFE & CRSP - 3 Healthcare Stocks With Low Investment Barriers and Stable Returns

      图片You can snag these three healthcare stocks for less than a grand and set yourself up for future success!1.PfizerNow is the perfect time to grab $Pfizer(PFE)$ stock. With 19 launches in 18 months and a string of acquisitions, including cancer expert $Seagen(SGEN)$ , Pfizer is poised to enter a new era of revenue growth.The stock is trading at a forward P/E ratio of 12, which is a steal considering the company's long-term potential.2.CRISPR Therapeutics $CRISPR Therapeutics AG(CRSP)$ has bagged the world's first regulatory approval for a CRISPR-based gene editing product. The company's recently approved product, Casgevy, treats sickle cell disease and beta-thalass
      2.55K3
      Report
      CRSP, PFE & CRSP - 3 Healthcare Stocks With Low Investment Barriers and Stable Returns
    • Value_investingValue_investing
      ·03-26

      Low-risk dividend stock NVS is worth buying!

      图片For passive income investors, $Novartis AG(NVS)$ , the Swiss pharmaceutical giant, is the perfect choice. It not only regularly increases its dividends but also avoids the risk of dividend cuts or suspensions.Novartis boasts 13 blockbuster drugs (with annual sales exceeding $1 billion), seven of which have seen growth in sales year-on-year. Its top-selling product remains Entresto, a heart failure drug, with revenue increasing by 30% to $6 billion. Meanwhile, Pluvicto, the first prostate cancer drug approved in the US in 2022, saw a staggering 262% year-on-year increase in sales to $980 million last year.In 2023, Novartis' net sales grew 8% to $45.4 billion, and earnings per share rose 18% to $6.47. Last year, the company spun off its generics an
      8323
      Report
      Low-risk dividend stock NVS is worth buying!
       
       
       
       

      Most Discussed

       
       
       
       
       

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial